CD147-CART
/ Air Force Medical University
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
June 08, 2022
CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia.
(PubMed, Cancer Lett)
- "NOD/ShiLtJGpt-Prkdcem26Cd52Il2rgem26Cd22/Gpt mice were used to establish a T-ALL xenograft model and CD147-CAR T cells conferred robust protection against T-ALL progression and significantly improved survival in mice. Overall, we found that CD147 is a potential antigen target of CAR T cell therapy for T-ALL."
CAR T-Cell Therapy • Journal • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • T Cell Non-Hodgkin Lymphoma • BSG • CCR7 • PRKDC
December 14, 2021
Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy.
(PubMed, Transl Oncol)
- "Importantly, CD147-CART cells have strong anti-tumor activity against NSCLC cells in vivo in both CDX and PDX models and no adverse side effects. Our findings show that CD147-CART immunotherapy for NSCLC is safe and effective, which is an ideal and promising medical patch for treating NSCLC."
CAR T-Cell Therapy • IO biomarker • Journal • Hematological Disorders • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BSG
May 07, 2020
CD147-CART Cells in Patients With Recurrent Malignant Glioma.
(clinicaltrials.gov)
- P1; N=31; Recruiting; Sponsor: Xijing Hospital; Active, not recruiting ➔ Recruiting
Clinical • Enrollment open
August 28, 2019
A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma
(clinicaltrials.gov)
- P1; N=34; Recruiting; Sponsor: Xijing Hospital; Active, not recruiting ➔ Recruiting
Clinical • Enrollment open
August 06, 2019
CD147-CART Cells in Patients With Recurrent Malignant Glioma.
(clinicaltrials.gov)
- P1; N=31; Active, not recruiting; Sponsor: Xijing Hospital
Clinical • New P1 trial
1 to 5
Of
5
Go to page
1